Interactions of antidepressants with concomitant medications—safety of complex therapies in multimorbidities
Authors:
Open Access
- 16 July 2024
- journal article
- review article
- Published by Springer Nature in Pharmacological Reports
- Vol. 76 (4) , 714-739
Abstract
Depression is the fourth most serious disease in the world. Left untreated, it is a cause of suicide attempts, emergence or exacerbation worsening of serious diseases, bodily and mental disorders, as well as increased risk of cardiovascular diseases, stroke, diabetes, and obesity, as well as endocrine and neurological diseases. Frequent coexistence of depression and other diseases requires the simultaneous use of several drugs from different therapeutic groups, which very often interact and intensify comorbidities, sometimes unrelated mechanisms. Sufficient awareness of potential drug interactions is critical in clinical practice, as it allows both to avoid disruption of proper pharmacotherapy and achieve substantive results. Therefore, this review aims to analyze the interactions of antidepressants with other concomitant medications. Against the backdrop of experimental research and a thorough analysis of the up-to-date literature, the authors discuss in detail the mechanisms and effects of action of individual drug interactions and adaptogens, including the latest antidepressants.Keywords
This publication has 127 references indexed in Scilit:
- Association of Youth Depression With Subsequent Somatic Diseases and Premature DeathJAMA Psychiatry, 2021
- Evolution of the adaptogenic concept from traditional use to medical systems: Pharmacology of stress‐ and aging‐related diseasesMedicinal Research Reviews, 2020
- New‐generation, non‐SSRI antidepressants: Drug‐drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and othersMedicinal Research Reviews, 2020
- Study of effects of ifenprodil in patients with methamphetamine dependence: Protocol for an exploratory, randomized, double‐blind, placebo‐controlled trialNeuropsychopharmacology Reports, 2019
- Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 updateClinical Pharmacology & Therapeutics, 2016
- Combination Therapy with Monoamine Oxidase Inhibitors and Other Antidepressants or Stimulants: Strategies for the Management of Treatment‐Resistant DepressionPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2015
- Differential Impact of Selective Serotonin Reuptake Inhibitors on Platelet Response to Clopidogrel: A Randomized, Double‐Blind, Crossover TrialPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2015
- Pharmacokinetic and Pharmacodynamic Evaluation of the Potential Drug Interaction Between Venlafaxine and DiazepamThe Journal of Clinical Pharmacology, 1995
- The Monoamine Oxidase Inhibitor—Tyramine InteractionThe Journal of Clinical Pharmacology, 1989
- Chemistry, Pharmacology, Pharmacokinetics, Adverse Effects, and Efficacy of the Antidepressant Maprotiline HydrochloridePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1981